IVT 8086
Alternative Names: IVT-8086Latest Information Update: 28 Aug 2024
At a glance
- Originator Innova Therapeutics
- Developer Innova Therapeutics; Medical University of South Carolina
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteosarcoma
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Osteosarcoma(Combination therapy) in USA (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Osteosarcoma(Monotherapy) in USA (Parenteral)
- 24 Sep 2020 Innova Therapeutics files a new drug application (NDA) for Osteosarcoma in USA, prior to September 2020